Breaking barriers: harnessing hypofractionated radiotherapy to transform outcomes in low tumor mutation burden stage III non-small cell lung cancer - a retrospective study
HFRT was superior to CFRT in prolonging PFS for patients with low-TMB locally advanced NSCLC. It was a safely and effective approach for these patients and was worth further prospective studies with larger sample sizes.
Authors
- Anmei Zhang (ORCID: https://orcid.org/0000-0001-8310-2827)
- Tianxiang Cui (ORCID: https://orcid.org/0000-0002-0102-2581)
- Jianguo Sun
- Guangpeng Chen
- H. J. Yang (ORCID: https://orcid.org/0009-0004-8274-9863)
- Guanghui Li (ORCID: https://orcid.org/0000-0003-0191-6005)
- Xinxin Wang (ORCID: https://orcid.org/0000-0001-8238-7832)
- Yang Zhang (ORCID: https://orcid.org/0000-0002-5786-7452)
Institutions
- Army Medical University (CN)
- Xinqiao Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1557154
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science and Technology Major Project